Open AccessChanges in renin‐angiotensin‐aldosterone system during cardiac remodeling after mitral valvuloplasty in dogs
Author(s) -
Cheng ChiehJen,
Mandour Ahmed S.,
Yoshida Tomohiko,
Watari Toshihiro,
Tanaka Ryou,
Matsuura Katsuhiro
Publication year - 2022
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/jvim.16346
Subject(s) - medicine , aldosterone , cardiology , creatinine , plasma renin activity , renin–angiotensin system , heart failure , endocrinology , blood pressure
Background Information regarding changes in renin‐angiotensin‐aldosterone system (RAAS) during cardiac remodeling after mitral valvuloplasty (MVP) in dogs remains lacking. Hypothesis/Objectives To assess the longitudinal effects of MVP on circulating RAAS activity. Animals Eight client‐owned dogs receiving MVP for myxomatous mitral valve disease (MMVD). Methods This is a cohort study. Plasma renin activity (PRA), angiotensin II (AT2), aldosterone (PAC), blood urea nitrogen (BUN), and creatinine concentrations, were measured in these dogs before (baseline) and at 3 consecutive monthly follow‐ups (Post‐1M, Post‐2M, Post‐3M). Echocardiography was concomitantly used to assess the process of cardiac recovery after MVP. Results The echocardiography revealed a significant decrease in LVIDDN, LA/Ao, FS, E velocity, E/A, E′ sep, S′ lat, E′ lat, and A′ lat after MVP compared with baseline ( P < .05). There was a significant reduction in the PRA (2.45, 3.05, 2.74 vs 8.8 ng/mL/h; P = .002), AT2 (466, 315, 235 vs 1200 pg/mL; P = .009), and PAC (39.88, 47, 54.62 vs 179.5 pg/mL; P = .01), respectively at Post‐1M, Post‐2M, Post‐3M compared to the baseline. Additionally, BUN and creatinine concentrations decreased from Post‐1M. The RAAS variables showed significant, weak to moderate, relationship with selected echocardiographic variables. Conclusions and Clinical Importance Mitral valvuloplasty contributes to decreased RAAS activity in MMVD dogs, which paralleled the process of cardiac reverse remodeling up to Post‐3M. This information facilitates formulating strategies to optimize clinical outcomes for dogs after MVP.